17 October 2024 - Temporary marketing authorisation is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT trial.

CSL Vifor and Travere Therapeutics today announced that Swiss Medic has granted temporary marketing authorisation for Filspari for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

Read CSL Vifor press release